Centre For Translational Pathology Research And Training
Funder
National Health and Medical Research Council
Funding Amount
$2,677,639.00
Summary
The Centre for Translational Pathology Research and Training is a collaborative network involving nine hospitals and research institutes affiliated with The University of Melbourne. It's goal is train a cadre of molecular pathologists experienced in collaborative multidisciplinary research who can effective translate research discoveries and inventions in to clinically useful diagnostic tests that will enable oncologists to individualise treatment decisions for patients with cancer, based on the ....The Centre for Translational Pathology Research and Training is a collaborative network involving nine hospitals and research institutes affiliated with The University of Melbourne. It's goal is train a cadre of molecular pathologists experienced in collaborative multidisciplinary research who can effective translate research discoveries and inventions in to clinically useful diagnostic tests that will enable oncologists to individualise treatment decisions for patients with cancer, based on the unique biology of the individual's tumour.Read moreRead less
Breast Cancer is a very common disease in women and although huge progress has been made in the last two decades, much remains to be done to improve our understanding of different types of breast cancer and its management. This program brings together the expertise of three senior researchers: 2scientists and 1 medical scientist. Dr Trench has an interest in identifying genes involved in cancers arising in patients who have a strong family history. She will use molecular methods and cohorts of p ....Breast Cancer is a very common disease in women and although huge progress has been made in the last two decades, much remains to be done to improve our understanding of different types of breast cancer and its management. This program brings together the expertise of three senior researchers: 2scientists and 1 medical scientist. Dr Trench has an interest in identifying genes involved in cancers arising in patients who have a strong family history. She will use molecular methods and cohorts of patients enrolled with Kathleen Cunningham Foundation for Research into Familial Breast and Ovarian Cancer to identify the genes responsible, assess their distribution in the population and determine whether these genes also play a role in non-familial cancers. Dr Khanna's work examines the complex array of enzymes that are responsible for maintaining the integrity of the DNA, and investigates how failure of these mechanisms leads to damage of the genetic material which ultimately results in cancer. It is known that genes involved in familial predisposition code for proteins that work as DNA repair enzymes. It is also known that different types of breast cancer exist, each with differing behaviour and response to treatment and that they are associated with specific genetic changes, including those associated with a familial predisposition. Prof Lakhani's interest lies in using microscopy and the latest molecular tools to refine the classification of these different types of breast tumour so that they can be managed appropriately by his surgical and oncological colleagues. A better understanding of the genetic changes and underlying biology of different types of breast cancer will lead to individualised and specific therapy for patients. This program brings together a unique combination, nationally and internationally, that investigates cancers at the level of genes and cells and translates the information to the clinic for the benefit of patient management.Read moreRead less
Using Chromosome Rearrangements As Tumour-specific Markers For Disease Monitoring In Lung Cancer Using Droplet Digital PCR
Funder
National Health and Medical Research Council
Funding Amount
$1,081,335.00
Summary
There are no useful markers apart from CT scans to determine the effectiveness of therapy in patients with lung cancer. We plan to assess highly sensitive methods that can examine the blood to determine whether DNA from the patient’s tumour is present. This will allow more responsive modulation of therapy to enable better management of the cancer.
Personalising Care In Operable Pancreas Cancer. GAP-T: A Study Of Imaging And Molecular Biomarkers To Guide Treatment Of Patients Receiving Preoperative Chemotherapy Followed By Surgery.
Funder
National Health and Medical Research Council
Funding Amount
$405,345.00
Summary
We are studying ways to improve how we treat patients with pancreatic cancer. We will use a novel imaging tool, the PET scanner, to show where active cancer is and how quickly and how well a new drug combination (gemcitabine and nab-paclitaxel) is affecting the cancer. We will also study if measuring the expression of specific proteins (SPARC and hENT1) in the cancer affects the outcome and will allow us to determine ahead of time which patients will benefit most from the drugs.
The Role Of FHL Proteins In The Pathology Of Muscular Dystrophies: Identification Of Novel Therapeutic Targets
Funder
National Health and Medical Research Council
Funding Amount
$61,355.00
Summary
Scientists at Monash University have recently identified a protein called FHL1 which promotes skeletal muscle repair-growth and may reverse the muscle degeneration seen in inherited muscular dystrophies. This study will investigate whether FHL1 expression can improve muscle mass in mouse models of muscular dystropy. In doing so, this research improve out understanding of the molecular processes that cause muscular dystrophies and thereby lead the way to new therapies for this family of diseases.
Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Novel Therapeutic Strategies Targeting Aberrant Cell Cycle Regulation In Pancreatic Cancer And Development Of Robust Tissue-based Assay For Biomarkers Of Therapeutic Responsiveness
Funder
National Health and Medical Research Council
Funding Amount
$139,177.00
Summary
The overall aim of my research to assess noel therapeutic strategies in pancreatic cancer. Using new technology, more in depth understanding of pancreatic cancers (PC) is allowing better characterisation of these tumour into distinct molecular phenotypes. Some of these phenotypes are showing response to specific therapies in experimental models. Hence, there is an urgent need to to define these responsive phenotypes to stratify patients to appropriate therapeutic regimens.
Host Resistance And Protection Against Oral Candidasis
Funder
National Health and Medical Research Council
Funding Amount
$196,527.00
Summary
Candida albicans is an important opportunistic pathogen, that is widely represented in general medical and dental practice, as well as in the hospital environment. Clinical observations indicate that defects in innate immunity predispose patients to disseminated infection, whereas a weakened cell-mediated immune response is commonly associated with chronic oral infections. Animal models of both chronic and acute oral candidiasis have been developed and characterised by the applicants, and these ....Candida albicans is an important opportunistic pathogen, that is widely represented in general medical and dental practice, as well as in the hospital environment. Clinical observations indicate that defects in innate immunity predispose patients to disseminated infection, whereas a weakened cell-mediated immune response is commonly associated with chronic oral infections. Animal models of both chronic and acute oral candidiasis have been developed and characterised by the applicants, and these have clearly implicated T cells in the process of recovery from primary infection. The models will now be used to analyse the effector mechanisms that lead to clearance of the yeast from the oral cavity, with a particular focus on the role of phagocytic cells, and their interaction with T cells. The acute model will be used to identify immunological variables that can act as markers of protection, and the effectiveness of therapeutic manipulations will be evaluated in the chronic model, with the ultimate aim of developing a protective vaccine for human infections.Read moreRead less
Discovering Novel Molecules That Regulate Axonal Degeneration.
Funder
National Health and Medical Research Council
Funding Amount
$588,622.00
Summary
The axon is the primary signaling component of every neuron and is essential for normal function. Axonal degeneration is a key early pathological hallmark of Alzheimer’s disease. We lack a basic understanding of molecules that regulate this process. Such knowledge is essential for the development of treatments and therapies for dementia and the preservation of healthy ageing. I aim to discover the molecules that regulate axonal degeneration and study their function.